Sinopharm Holdings (02096): The anti-insomnia drug Kewei has been approved by the National Medical Products Administration to be launched in China.

Zhtng Cijng APP news, Xiansheng Pharmaceuticals (02096) announced that on June 20, 2025, the group's collaboration with Idorsia Pharmaceuticals Ltd. yielded approval from the China National Medical Products Administration (NMPA) for the listing of the insomnia treatment drug Doria (D-Lysine Clonazepam) in China. This medication is used for the treatment of adult insomnia patients with features of difficulty falling asleep and/or maintaining sleep, and is not controlled as a psychiatric drug.